Alberto Catalano

All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

Harry Iland, Ken Bradstock, Shane G. Supple et al. · Blood · 2012 · 340 citations · Full text

Medicine, Hematology, Oncology +15

Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial

Harry Iland, Marnie Collins, Ken Bradstock et al. · The Lancet Haematology · 2015 · 170 citations

Medicine, Hematology, Oncology +10

The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia

Alberto Catalano, Mark A. Dawson, Karthiga Somana et al. · Blood · 2007 · 132 citations · Full text

Life Sciences, Genetics, Molecular Genetics +9

Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1

Silvia Ling, Edwin Lau, Ammira Al-Shabeeb et al. · Haematologica · 2011 · 129 citations · Full text

Medicine, Biochemistry, Oncology +13

Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia

Harry Iland, K. F. Bradstock, John F. Seymour et al. · Haematologica · 2011 · 59 citations · Full text

Medicine, Oncology, Pharmacology +15